Literature DB >> 33415438

Does the appearance of the cutaneous scar after cesarean section reflect the residual myometrial thickness?

Ammar Al Naimi1,2, Niki Mouzakiti3, Carmen Eißmann3, Frank Louwen4, Franz Bahlmann3.   

Abstract

PURPOSE: The aim of this study is to utilize the Manchester scar scale (MSS) and ultrasound in investigating the association between uterine wall defects and cutaneous scar characteristics after cesarean section (CS).
METHODS: This is a prospective cohort study. The degree of myometrial loss was quantified by calculating a residual myometrial thickness (RMT) ratio as a percentage of RMT to the pre-cesarean anterior uterine wall thickness. Cutaneous scar assessment was performed according to the MSS. Spearman's correlation and the Kruskal-Wallis test with a cut-off value of p < 0.05 were used for statistical analysis.
RESULTS: Two hundred forty seven women, of which 2.4% had an Asian, 3.6% an Afro-American, 82% a Caucasian and 12% a Mediterranean background, were recruited. The RMT ratio ranged between 11.9 and 100% with a median of 55.8% and an average of 56%. MSS scores ranged from 4 to 13 with a median of 5 and an average of 6. Spearman's correlation between MSS and RMT ratio show a rho of - 0.01 with a p value of 0.8. The correlation between MSS and RMT ratio within the four ethnical groups showed a p value between 0.3 and 0.8 and a rho between 0.8 and - 0.8. The Kruskal-Wallis test showed an eta2 of 0.13 and a p value of 0.0002 for the effect of ethnicity on MSS and an eta2 of 0.009 and a p value of 0.68 for the effect of ethnicity on the RMT ratio.
CONCLUSION: CS laparotomy scars heal differently between ethnical groups, but generally with satisfying results. Ethnicity does not affect myometrial healing and scar appearance does not reflect myometrial healing after CS. Thus, separate uterine sonographic assessment is recommended.

Entities:  

Keywords:  Cesarean section; Manchester scar scale; Residual myometrial thickness; Ultrasound

Mesh:

Year:  2021        PMID: 33415438      PMCID: PMC7960579          DOI: 10.1007/s00404-020-05943-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  Ribonucleic acid synthesis in Streptomyces antibioticus: stable ribonucleic acid species synthesized by young and old cells.

Authors:  G H Jones
Journal:  Biochem Biophys Res Commun       Date:  1975-03-17       Impact factor: 3.575

2.  Cytokine and growth factor mRNA expression patterns associated with the hypercontracted, hyperpigmented healing phenotype of red duroc pigs: a model of abnormal human scar development?

Authors:  Corrie L Gallant-Behm; Merle E Olson; David A Hart
Journal:  J Cutan Med Surg       Date:  2005-08       Impact factor: 2.092

3.  Does ultrasound-guided intervention during repeat cesarean sections improve uterine scar architecture and reduce the number of scars? A prospective controlled clinical intervention trial.

Authors:  Gregor Seliger; Anne Muendane; Katharina Chaoui; Grit Gesine Ruth Hiller; Christine Lautenschläger; Serban-Dan Costa; Michael Tchirikov
Journal:  J Perinat Med       Date:  2018-10-25       Impact factor: 1.901

4.  Uterine Wound Healing: A Complex Process Mediated by Proteins and Peptides.

Authors:  Dario D Lofrumento; Maria A Di Nardo; Marianna De Falco; Andrea Di Lieto
Journal:  Curr Protein Pept Sci       Date:  2017       Impact factor: 3.272

Review 5.  Cutaneous wound healing: recruiting developmental pathways for regeneration.

Authors:  Kirsten A Bielefeld; Saeid Amini-Nik; Benjamin A Alman
Journal:  Cell Mol Life Sci       Date:  2012-10-04       Impact factor: 9.261

6.  Effectiveness of negative pressure wound therapy in the prevention of surgical wound complications in the cesarean section at-risk population: a parallel group randomised multicentre trial-the CYGNUS protocol.

Authors:  Kylie Sandy-Hodgetts; Richard Parsons; Richard Norman; Mark W Fear; Fiona M Wood; Scott W White
Journal:  BMJ Open       Date:  2020-10-19       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.